HSP90 inhibitors in lung cancer: Promise still unfulfilled

Clinical Advances in Hematology and Oncology

Volumn 14, Issue 5, 2016, Pages 346-356

  Chatterjee, Suman ^a   Bhattacharya, Saveri ^a   Socinski, Mark A ^a   Burns, Timothy F ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

ALK; EGFR; HSP90 inhibitors; Lung cancer; Oncogenic drivers

Indexed keywords

4 [[2 CARBAMOYL 5 (4,5,6,7 TETRAHYDRO 6,6 DIMETHYL 4 OXO 3 (TRIFLUOROMETHYL) 1H INDAZOL 1 YL)PHENYL]AMINO]CYCLOHEXYL GLYCINATE; ALECTINIB; ALVESPIMYCIN; ANAPLASTIC LYMPHOMA KINASE; ANDROGEN RECEPTOR; B RAF KINASE; CERITINIB; CHECKPOINT KINASE 1; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GANETESPIB; GEFITINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; K RAS PROTEIN; LUMINESPIB; ONALESPIB; PACLITAXEL; PROTEIN KINASE B; RAPAMYCIN; RETASPIMYCIN; SCATTER FACTOR RECEPTOR; TANESPIMYCIN; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ARTICLE; CELL CYCLE CHECKPOINT; DNA REPAIR; DRUG STRUCTURE; GENE MUTATION; HUMAN; LUNG CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; GENE AMPLIFICATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PRECLINICAL STUDY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CLINICAL TRIALS AS TOPIC; DNA REPAIR; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GENE AMPLIFICATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84966601931     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Somasundaram A, Socinski MA, Burns TF. Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opin Pharmacother. 2014;15(18):2693-2708.
3. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18(1):64-76.
4. Ochiana SO, Taldone T, Chiosis G. Designing drugs against Hsp90 for cancer therapy. In: Houry WA, ed. The Molecular Chaperones Interaction Networks in Protein Folding and Degradation. Vol 1. New York, NY: Springer; 2014:151-183.
5. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425(6956):407-410.
6. Soga S, Neckers LM, Schulte TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res. 1999;59(12):2931-2938.
7. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005;23(18):4152-4161.
8. Jang WJ, Jung SK, Kang JS, et al. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification. Cancer Sci. 2014;105(10):1245-1253.
9. Ueno T, Tsukuda K, Toyooka S, et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer. Lung Cancer. 2012;76(1):26-31.
10. Brough PA, Aherne W, Barril X, et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem. 2008;51(2):196-218.
11. Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012;11(2):475-484.
12. Fadden P, Huang KH, Veal JM, et al. Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol. 2010;17(7):686-694.
13. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.
14. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
15. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 2005;65(14):6401-6408.
16. Ge J, Normant E, Porter JR, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006;49(15):4606-4615.
17. Nguyen DM, Desai S, Chen A, Weiser TS, Schrump DS. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg. 2000;70(6):1853-1860.
18. Yang S, Qu S, Perez-Tores M, et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 2006;66(14):6990-6997.
19. Hong YS, Jang WJ, Chun KS, Jeong CH. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR. Oncol Rep. 2014;31(6):2619-2624.
20. Kobayashi N, Toyooka S, Soh J, et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer. 2012;75(2):161-166.
21. Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008;68(14):5827-5838.
22. Garon EB, Finn RS, Hamidi H, et al. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013;12(6):890-900.
23. Shimamura T, Perera SA, Foley KP, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012;18(18):4973-4985.
24. Graham B, Curry J, Smyth T, et al. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci. 2012;103(3):522-527.
25. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
26. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566.
27. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535-7540.
28. Chen Z, Sasaki T, Tan X, et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 2010;70(23):9827-9836.
29. Normant E, Paez G, West KA, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene. 2011;30(22):2581-2586.
30. Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov. 2013;3(4):430-443.
31. Wallis N, Smyth T, Munck J, et al. Activity of the HSP90 inhibitor, AT13387, in ALK-driven tumor models [EORTC abstract 293]. Eur J Cancer. 2012;48(6 suppl):90.
32. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6(2):201-205.
33. Sos ML, Michel K, Zander T, et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009;119(6):1727-1740.
34. De Raedt T, Walton Z, Yecies JL, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011;20(3):400-413.
35. Acquaviva J, Smith DL, Sang J, et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther. 2012;11(12):2633-2643.
36. Gomez-Casal R, Bhattacharya C, Epperly MW, et al. The HSP90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells. Cancers (Basel). 2015;7(2):876-907.
37. Proia DA, Sang J, He S, et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 2012;30(6):2201-2209.
38. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
39. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-525.
40. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550.
41. Camidge DR, Ou SH, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [ASCO abstract 8001]. J Clin Oncol. 2014;32(5)(suppl).
42. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850-859.
43. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842-849.
44. Choi YJ, Kim SY, So KS, et al. AUY922 effectively overcomes MET-and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One. 2015;10(3):e0119832.
45. Rice JW, Veal JM, Barabasz A, et al. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib. Oncol Res. 2009;18(5-6):229-242.
46. Koizumi H, Yamada T, Takeuchi S, et al. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol. 2012;7(7):1078-1085.
47. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH; Eastern Cooperative Oncology Group Study 2598. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol. 2004;22(7):1180-1187.
48. Xu W, Soga S, Beebe K, et al. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br J Cancer. 2007;97(6):741-744.
49. Zheng FF, Kuduk SD, Chiosis G, et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res. 2000;60(8):2090-2094.
50. Nogova L, Mattonet C, Scheffler M, et al. TRY-A phase II study to evaluate safety and efficacy of combined trastuzumab and the Hsp90 inhibitor AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation [ESMO abstract 1238P]. Ann Oncol. 2014;25(suppl 4):iv433.
51. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570-4579.
52. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190-1203.
53. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-381.
54. Ju YS, Lee WC, Shin JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22(3):436-445.
55. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375-377.
56. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382-384.
57. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29(15):2046-2051.
58. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
59. Smyth T, Paraiso KH, Hearn K, et al. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther. 2014;13(12):2793-2804.
60. Paraiso KH, Haarberg HE, Wood E, et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012;18(9):2502-2514.
61. Nguyen DM, Lorang D, Chen GA, Stewart JH IV, Tabibi E, Schrump DS. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg. 2001;72(2):371-378.
62. Sawai A, Chandarlapaty S, Greulich H, et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res. 2008;68(2):589-596.
63. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol Chem. 2003;278(52):52572-52577.
64. O'Connell BC, O'Callaghan K, Tillotson B, et al. HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer. PLoS One. 2014;9(12):e115228.
65. Senju M, Sueoka N, Sato A, et al. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol. 2006;132(3):150-158.
66. Koll TT, Feis SS, Wright MH, et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther. 2008;7(7):1985-1992.
67. Bansal H, Bansal S, Rao M, et al. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood. 2010;116(22):4591-4599.
68. Saif MW, Erlichman C, Dragovich T, et al. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71(5):1345-1355.
69. Wagner AJ, Chugh R, Rosen LS, et al. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013;19(21):6020-6029.
70. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010;28(33):4953-4960.
71. Riely GJ, Stoller RG, Egorin M, et al. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel [ASCO abstract 3547]. J Clin Oncol. 2009;27(15)(suppl).
72. Modi S, Saura C, Henderson C, et al. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Res Treat. 2013;139(1):107-113.
73. Sessa C, Shapiro GI, Bhalla KN, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res. 2013;19(13):3671-3680.
74. Garon EB, Moran T, Barlesi F, et al. Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC) [ASCO abstract 7543]. J Clin Oncol. 2012;30(15)(suppl).
75. Johnson ML, Yu HA, Hart EM, et al. Phase I/II study of HSP90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2015;33(15):1666-1673.
76. Piotrowska Z, Costa DB, Huberman M, et al. Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions [ASCO abstract 8015]. J Clin Oncol 2015;33(15)(suppl).
77. Vermes K. Vernalis PLC (VNLPY.PK) stumbles as Novartis AG (NVS) abandons work on AUY922. BioSpace.com. http://www.biospace.com/News/vernalis-plc-stumbles-as-novartis-ag-abandons-work/358835. Posted December 19, 2014. Accessed March 1, 2016.
78. Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013;13:152.
79. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013;19(11):3068-3077.
80. Ramalingam S, Goss G, Rosell R, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015;26(8):1741-1748.
81. Ramalingam SS, Zaric B, Ceric T, et al. Galaxy-2 trial (NCT01798485): a randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma [ASCO abstract TPS8118^]. J Clin Oncol 2014;32(15)(suppl).
82. Synta announces termination for futility of ganetespib phase 3 GALAXY-2 trial in lung cancer. BusinessWire.com. http://www.businesswire.com/news/ home/20151020006900/en/Synta-Announces-Termination-Futility-Ganetespib-Phase-3. Posted October 20, 2015. Accessed March 1, 2016.
83. Mahadevan D, Rensvold DM, Kurtin SE, et al. First-in-human phase I study: results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors [ASCO abstract 3028]. J Clin Oncol. 2012;30(15)(suppl).
84. McDowell CL, Bryan Sutton R, Obermann WM. Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue. Int J Biol Macromol. 2009;45(3):310-314.
85. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537-549.
86. Donnelly A, Blagg BSJ. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem. 2008;15(26):2702-2717.
87. Zhang T, Hamza A, Cao X, et al. A novel Hsp90 inhibitor to disrupt Hsp90/ Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther. 2008;7(1):162-170.
88. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res. 2000;6(8):3312-3318.
89. Proia DA, Smith DL, Zhang J, et al. HSP90 Inhibitor-SN-38 conjugate strategy for targeted delivery of topoisomerase I inhibitor to tumors. Mol Cancer Ther. 2015;14(11):2422-2432.